Skip to content

Study · Randomized controlled trial · n = 24 · 2026

11 results

Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover Study.

Gether IM, Kliim-Hansen V, Olafsson PT, Pedersen MG, Nielsen CK, Ellegaard AM, Christensen MB, Rehfeld JF, Helge JW, Holst JJ, Hartmann B, Knop FK, Gasbjerg LS, Lund AB

Diabetes, obesity & metabolism10 Mar 2026

PMID41804830 (opens in a new tab)PMCIDPMC13146140 (opens in a new tab)DOI10.1111/dom.70637 (opens in a new tab)PepBankPUB-41804830
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin infusion did not change ad libitum food intake compared with saline.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change how much people ate at a meal compared with saline.

    Peptide
    Oxytocin
    Outcome
    No significant changeAd libitum food intake
    Study

    n = 24

    Comparator
    Placebo (saline)
    Analysis
    Primary
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Measurements

    Ad libitum food intake
    714 kcal
    oxytocin
    Ad libitum food intake
    707 kcal
    saline

    Source sentences

    Summary
    Ad libitum food intake was similar between oxytocin and saline infusions (mean 714 ± SD 382 vs. 707 ± 385 kcal).
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect appetite sensations compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change feelings of appetite compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeAppetite sensations
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating glucose compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change blood sugar compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating glucose
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating insulin compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change insulin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating insulin
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating C-peptide compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change C-peptide levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating C-peptide
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating glucagon compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change glucagon levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating glucagon
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating glucagon-like peptide 1 compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change GLP-1 hormone levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating GLP-1
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating glucose-dependent insulinotropic polypeptide compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change GIP hormone levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating GIP
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect circulating cholecystokinin compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change cholecystokinin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating cholecystokinin
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, intravenous oxytocin did not affect plasma paracetamol, the marker of gastric emptying, compared with placebo.

    In plain wordsIn adults with obesity, an oxytocin infusion did not change how fast the stomach emptied compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeGastric emptying (plasma paracetamol)
    Study

    n = 24

    Comparator
    Placebo (saline)
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin did not affect sensations of appetite nor circulating glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, cholecystokinin, or paracetamol.
    3 context sentences
    Summary · context
    After 60 min of infusion, participants ingested a standardised liquid mixed meal containing 1.5 g paracetamol (for evaluation of gastric emptying).
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.
  11. 11HumanRandomized controlled trialPharmacokinetics

    In adults with obesity, the 4.5-hour intravenous oxytocin infusion produced supraphysiological plasma concentrations of about 400 pg/mL.

    In plain wordsIn adults with obesity, the oxytocin infusion gave blood levels of about 400 pg/mL, above natural levels.

    Peptide
    Oxytocin
    Outcome
    Not applicablePlasma oxytocin concentration during infusion
    Study

    n = 24

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.2 international units/min · intravenous · 4.5 hoursAs given in this study (human).

    Measurements

    Plasma oxytocin
    ≈ 400 pg/mL
    intravenous infusion

    Source sentences

    Summary
    4.5-hour intravenous infusion of oxytocin causing supraphysiological plasma concentrations of ~400 pg/mL
    2 context sentences
    Summary · context
    In a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days.
    Summary · context
    Twenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m2, mean glycated haemoglobin 34 ± standard deviation (SD) 3.5 mmol/mol) completed the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.